Pharmacokinetic Profile of Beclomethasone Dipropionate Hydrofluoroalkane After Intranasal Administration Versus Oral Inhalation in Healthy Subjects: Results of a Single-Dose, Randomized, Open-Label, 3-Period Crossover Study

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages 1422-1431

  Ratner, Paul H ^a   Melchior, Amy ^b   Dunbar, Stephanie A ^b   Tantry, Sudeesh K ^b   Dorinsky, Paul M ^b  

^a Sylvana Research Associates   (United States)

^b Teva Branded Pharmaceutical Products R and D Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETHASONE 17 MONOPROPIONATE; DRUG METABOLITE; FLUORINATED HYDROCARBON; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADULT; AREA UNDER CURVE; BECLOMETHASONE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; REFERENCE VALUES;

EID: 84862116335     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.023     Document Type: Article

References (18)

1. Greiner A.N., Hellings P.W., Rotiroti G., Scadding G.K. Allergic rhinitis. Lancet 2011, 378:2112-2122.
2. Wallace D.V., Dykewicz M.S., Bernstein D.I., et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008, 122(Suppl 2):S1-S84.
3. Skoner D.P. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001, 108(Suppl 1):S2-S8.
4. Bousquet J. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S147-S334. ARIA Workshop Group.
5. Weiner J.M., Abramson M.J., Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998, 317:1624-1629.
6. Luskin A.T., Blaiss M.S., Farrar J.R., et al. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis. Allergy Asthma Proc 2011, 32:168-177.
7. Fromer L.M., Ortiz G., Ryan S.F., Stoloff S.W. Insights on allergic rhinitis from the patient perspective. J Fam Pract 2012, 61(Suppl 2):S16-S22.
8. Naclerio R.M., Hadley J.A., Stoloff S., Nelson H.S. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 2007, 28:S11-S17.
9. Beconase AQ (beclomethasone dipropionate, monohydrate) nasal spray, 42 mcg 2005, [prescribing information], GlaxoSmithKline, Research Triangle Park, NC.
10. Montreal Protocol Accessed September 28, 2011. http://www.epa.gov/ozone/intpol/.
11. QVAR 40 mcg (beclomethasone dipropionate HFA, 40 mcg) inhalation aerosol for oral inhalation only; QVAR 80 mcg (beclomethasone dipropionate HFA, 80 mcg) inhalation aerosol for oral inhalation only 2010, [prescribing information], Teva Respiratory, LLC, Horsham, PA.
12. Meltzer E.O., Jacobs R.L., LaForce C.F., Kelley L., Dunbar S.A., Tantry S.K. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc 2012, 33:249-257.
13. Daley-Yates P.T., Price A.C., Sisson J.R., Pereira A., Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001, 51:400-409.
14. Soria I., Harrison L.I., Machacek J.H., Cline A.C., Stampone P.A. Beclomethasone relative availability of oral versus inhaled beclomethasone dipropionate from an HFA-134A metered dose inhaler. Biopharm Drug Dispos 1998, 19:297-302.
15. Allen D.B. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 2006, 53:101-110.
16. Winkler J., Hochhaus G., Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 2004, 1:356-363.
17. Cave A., Arlett P., Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999, 83:153-179.
18. Nave R., Herzog R., Laurent A., Wingertzahn M.A. Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers. Clin Ther 2009, 31:2988-2999.